Could a diabetes drug stop AFib from coming back?
NCT ID NCT06528262
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether enavogliflozin, a drug originally for diabetes, can prevent atrial fibrillation (AF) from returning after a catheter ablation procedure in people with AF and heart failure. About 390 adults will receive either the drug or a placebo daily for a year. The main goal is to see if the drug reduces AF recurrence between 3 months and 1 year after the procedure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Enavogliflozin (a type of SGLT2 inhibitor drug, originally used for diabetes)
What this could lead to
If it works, this could provide a new way to prevent atrial fibrillation from coming back after a common heart procedure, especially for people with heart failure.
What could go wrong
This is a Phase 4 trial, but it is still relatively small (390 people) and only tests one drug. Previous studies were mostly in people with diabetes, so results may not apply to everyone. The drug may not reduce recurrence significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Severance Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••